Hypomagnesemia is evidenced in cancer patients after cisplatin-based chemotherapies [168], and it has emerged as the most notable adverse effect of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody, cetuximab, which is used widely for the treatment of advanced colorectal cancer cells [169]. This evidence concerns the gene EGFR and colorectal cancer.